Cystic fibrosis: A novel pharmacologic approach to cystic fibrosis transmembrane regulator modulation therapy

Journal of the American Osteopathic Association

Volumn 115, Issue 9, 2015, Pages 546-555

  Virant Young, Deborah ^a   Thomas, Justin ^b,c   Woiderski, Sarah ^b,d   Powers, Michelle ^b   Carlier, Joseph ^b   McCarty, James ^b   Kupchick, Tyler ^b   Larder, Anthony ^b  

^a Department of Pharmacology and Toxicology ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c PROVIDENCE HOSPITAL   (United States)

^d Huron Valley Sinai Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; ATALUREN; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; IVACAFTOR; LUMACAFTOR; OXADIAZOLE DERIVATIVE; QUINOLONE DERIVATIVE;

CYSTIC FIBROSIS; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MUTATION;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION; OXADIAZOLES; QUINOLONES;

EID: 84956496199     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: 10.7556/jaoa.2015.112     Document Type: Review

References (37)

1. Cystic Fibrosis Foundation. Patient registry annual data report 2013. https://www.cff.org/2013_CFF_Patient_Registry_Annual_Data_Report.pdf. Accessed July 30, 2015.
2. Narasimhan M, Cohen R. New and investigational treatments in cystic fibrosis. Ther Adv Respir Dis. 2011;5(4):275-282.
3. Ramsey B, Davies J, McElvaney N, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.
4. McCormick J, Green MW, Mehta G, et al. Demographics of the UK cystic fibrosis population: implications for neonatal screening. Eur J Hum Genet. 2002;10(10):583-590.
5. Gershman AJ, Mehta AC, Infeld M, Budey MM. Cystic fibrosis in adults: an overview for the internist. Cleve Clin J Med. 2006;73(12):1065-1074.
6. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90(3):1888-1896.
7. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992-2001.
8. Wilschanski M, Kerem E. New drugs for cystic fibrosis. Expert Opin Investig Drugs. 2011;20(9):1285-1292.
9. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251-1254.
10. Pettits R. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. [published online June 26, 2012] Ann Pharmacother. 2012;46(7-8):1065-1074. doi:10.1345/aph1.R076.
11. Lubamba B, Dhooghe B, Noel S, et al. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem. 2012;45(15):1132-1144.
12. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349(15):1433-1441.
13. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations. Pediatr Pulmonol. 2013;48(11):1047-1061.
14. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop codons. Nat Med. 1996;2(4):467-469.
15. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001;163(7):1683-1692.
16. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci. 2007;64(14):1841-1852.
17. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 2007;5:5.
18. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372(9640):719-727.
19. Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med. 2013;64:28.407-425.
20. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011;38(1):59-69.
21. Ryan N J. Ataluren: first global approval. Drugs. 2014;74(14):1709-1714.
22. Pettit RS, Fellner C. CFTR modulators for the treatment of cystic fibrosis. PT. 2014;39(7):500-511.
23. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011;180(46):18843-18848.
24. Boyle M, Bell S, Konstan MW, et al. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508del-CFTR mutation [abstract 212]. Pediatr Pulmonol. 2011;S34(suppl):287. doi:10.1002/ppul.21583.
25. Clancy JP, Rowe SM, Accurso FJ, et al. Results of phase IIa study of VX-809, an investigational CFTR corrector compound in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12-18.
26. Quintana-Gallego E, Delagado-Pecellin I, Acuna CC. CFTR protein repair therapy in cystic fibrosis. Arch Bronconeumol. 2014;50(4):146-150.
27. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.
28. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for F508del-CFTR mutation. Chest. 2012;142(3):718-724.
29. KALYDECO (ivacaftor) Tablets, for oral use [package insert]. Boston, MA: Vertex Pharmaceuticals Inc; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203188s004lbl.pdf. Accessed September 29, 2014.
30. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibrosis. 2012;11(3):237-245.
31. Pettit R, Fellner C. CFTR modulators for the treatment of cystic fibrosis. P T. 2014;39(7):500-511.
32. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Eng J Med. 2015;373:220-231. doi:10.1056/NEJMoa1409547.
33. Two 24-week phase 3 studies of lumacaftor in combination with ivacaftor met primary endpoint with statistically significant improvements in lung function (FEV1) in people with cystic fibrosis who have two copies of the F508del mutation [press release]. Boston, MA: Business Wire; June 24, 2014. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185. Accessed January 11, 2015.
34. Eckford PDW, Ramjeesigh M, Molinski S, et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol. 2014;21(5):666-678.
35. Donaldson S. Study of VX-661 alone and in combination with ivacaftor in subjects homozygous or heterozygous to the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation. ClinicalTrials.gov website. http://clinicaltrials.gov/show/NCT01531673. Accessed May 12, 2014.
36. Moss R. Study of ivacaftor in subjects with cystic fibrosis (CR) who have the R117H-CF transmembrane conductance regulator (CFTR) mutation (KONDUCT). ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show /study/NCT01614457. Accessed May 12, 2014.
37. Vankeerberghen A, Cuppens H, Cassiman JJ. The cystic fibrosis transmembrane conductance regulator: an intiriguing protein with pleiotropic functions. J Cyst Fibros. 2002;1(1):13-29.